CMS advises Optimapharm Group on the acquisition of Denothex AG

CMS advises Optimapharm Group on the acquisition of Denothex AG

Optimapharm, a leading independent clinical research organization providing customized solutions for clients and having vast expertise in managing clinical trials across Europe, acquires Denothex AG.

Denothex AG is a clinical research organization managing clinical trials of all phases, with particular focus on biotechnology and medical devices in oncology. By virtue of the acquisition of Denothex AG, Optimapharm is expanding its presence in the Central European market by strengthening its service offering to biotech and medical device companies and thus broadening its customer base. By combining continuous organic growth and selective investments in complementary organizations, Optimapharm has established itself as one of the leading players in the field of clinical research in Europe.

A team from CMS Switzerland, led by partner Stephan Werlen, advised Optimapharm Group on all legal matters of the transaction.

CMS Switzerland

Dr Stephan Werlen, Partner, Corporate / M&A
Pascal Stocker, Associate, Corporate / M&A
Dr Simone Brauchbar Birkhäuser, Counsel, Intellectual Property
Dr Felix Kesselring, Counsel, Life Sciences & Healthcare